Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 2/20 | 0.41 |
| ▸ | MMP13 | P45452 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5238513 | 0.73 | BCHE (0.44) | ALDH1A1POLB | |
| SCHEMBL30988189 | 0.73 | CHRNB2 (0.33) | ALDH1A1 | |
| SCHEMBL14410727 | 0.73 | TSHR (0.45) | ALDH1A1 | |
| SCHEMBL21262205 | 0.73 | TSHR (0.45) | ALDH1A1 | |
| SCHEMBL6999686 | 0.72 | ALDH1A1 (0.48) | ALDH1A1POLBHTT | |
| SCHEMBL5240426 | 0.68 | BCHE (0.43) | ALDH1A1POLB | |
| SCHEMBL9767014 | 0.68 | GRM2 (0.51) | ALDH1A1POLBHTTGRM2MMP1 | |
| SCHEMBL4096799 | 0.68 | GRM2 (0.58) | ALDH1A1POLBHTTGRM2MMP1 | |
| SCHEMBL4332334 | 0.68 | GRM2 (0.58) | ALDH1A1POLBHTTGRM2MMP1 | |
| SCHEMBL4332336 | 0.68 | GRM2 (0.58) | ALDH1A1POLBHTTGRM2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1326867-A2 | BRIDGED PIPERAZINE DERIVATIVES | Pfizer Products Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20020119961-A1 | Bridged piperazine derivatives | PFIZER INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002032901-A2 | BRIDGED PIPERAZINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119961-A1 | Bridged piperazine derivatives | MYD88, IL4, ARG1 | ALDH1A1 772/4885POLB 3658/4885HTT 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.